Pulmonology

ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements

ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.

BRINSUPRI® First Therapy Approved for NCFB at ATS 2026

BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.

Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026

ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.

Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use

New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.

YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients

YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps

New insights from ATS 2026 reveal significant discrepancies between patient experiences and pulmonologist perceptions in IPF and PPF management.

AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma

Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.

Epithelial Dysfunction: A Unified Target in Airway Disease Management

ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.

AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data

AIRSUPRA® (albuterol/budesonide) demonstrated a reduction in asthma exacerbations, addressing the need for improved rescue therapy.

IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction

IL-33 acts as both a pro-inflammatory cytokine and a contributor to mucus hypersecretion in COPD, complicating therapeutic targeting.